The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?

Detalles Bibliográficos
Autores principales: Matsumoto, Takashi, Shiota, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658146/
https://www.ncbi.nlm.nih.gov/pubmed/33209696
http://dx.doi.org/10.21037/tau-20-866
_version_ 1783608604696248320
author Matsumoto, Takashi
Shiota, Masaki
author_facet Matsumoto, Takashi
Shiota, Masaki
author_sort Matsumoto, Takashi
collection PubMed
description
format Online
Article
Text
id pubmed-7658146
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-76581462020-11-17 The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer? Matsumoto, Takashi Shiota, Masaki Transl Androl Urol Editorial Commentary AME Publishing Company 2020-10 /pmc/articles/PMC7658146/ /pubmed/33209696 http://dx.doi.org/10.21037/tau-20-866 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Matsumoto, Takashi
Shiota, Masaki
The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
title The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
title_full The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
title_fullStr The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
title_full_unstemmed The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
title_short The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
title_sort established risk of prostate cancer comorbidity in brca1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658146/
https://www.ncbi.nlm.nih.gov/pubmed/33209696
http://dx.doi.org/10.21037/tau-20-866
work_keys_str_mv AT matsumototakashi theestablishedriskofprostatecancercomorbidityinbrca12mutationcarrierswhereistheclinicallyrelevanthotspotforprostatecancer
AT shiotamasaki theestablishedriskofprostatecancercomorbidityinbrca12mutationcarrierswhereistheclinicallyrelevanthotspotforprostatecancer
AT matsumototakashi establishedriskofprostatecancercomorbidityinbrca12mutationcarrierswhereistheclinicallyrelevanthotspotforprostatecancer
AT shiotamasaki establishedriskofprostatecancercomorbidityinbrca12mutationcarrierswhereistheclinicallyrelevanthotspotforprostatecancer

Ejemplares similares